Rare Kidney Diseases Market is expected to Observe Considerable Growth Opportunities to 2031

Rare Kidney Diseases Market to is Projected to Grow at a CAGR of 16%, During the Period 2022-2030, claims InsightAce Analytic

InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Rare Kidney Diseases Market By Target Indications (IgA Nephropathy, Membranous Nephropathy, Lupus Nephritis, C3 Glomerulopathy, Focal Segmental Glomerular Sclerosis, and Others), Type of Molecule (Small Molecules and Biologics (Hormone, Monoclonal Antibody, Recombinant Protein, and Others)), Route of Administration (Intravenous, Oral, Subcutaneous, and Others))- Market Outlook and Industry Analysis 2030"

Get Free Access to Demo Report, Excel Pivot and ToC :https://www.insightaceanalytic.com/request-sample/1414

The company's most recent study indicates that the global market for uncommon kidney diseases is expected to grow at a promising 16% CAGR from 2022 to 2030.

There are about 150 different illnesses that fall under the category of rare renal diseases (RKD). According to estimates, there are 60 to 80 cases of uncommon kidney illnesses for every 100,000 people in the US and Europe. Patients with renal illness have a five to ten times higher risk of dying young than those who get kidney failure replacement treatment (KFRT). Notably, treating patients with uncommon kidney illnesses got considerably more difficult once the COVID-19 epidemic began. The pharmaceutical industry has been compelled by the increase in mortality rates to conduct the necessary research to develop new medications that can successfully treat uncommon kidney illnesses. Kidney disease may be present in about one-third of people with diabetes and one-fifth of adults with hypertension. According to data from the 2018 NVS 2021 report, kidney disorders claim more lives than both breast and prostate cancer combined. Illness has a five to ten times higher risk of dying young than those who get kidney failure replacement treatment (KFRT). With uncommon kidney illnesses, it got considerably more difficult once the COVID-19 epidemic began. This is primarily because most current therapies for these disorders require frequent hospital or medical centre visits. This led to a 30% increase in the number of sick people dying during the pandemic. The pharmaceutical industry has been compelled by the rise in mortality rates to conduct the necessary research to develop new medications that can successfully treat uncommon kidney illnesses.

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

The Market for uncommon kidney diseases is growing due to several important considerations. With new developments in diagnosis and treatment, the demand for complicated illnesses is increasing due to the cooperation between doctors, patients, industry representatives, regulatory bodies, and government organizations. Furthermore, the growing application of next-generation sequencing methods would enhance the precision of diagnosis for uncommon kidney disorders, help clarify the molecular causes of the illness, ease genetic counselling, and open up carrier testing options. Improvements in renal replacement therapy and its accessibility allow patients to live longer, albeit at the cost of their quality of life.

Therapeutic advancements in rare kidney diseases have been hampered by market-restraining factors such as unresolved genetic defects, a lack of biomarkers to track disease progression, heterogeneous clinical phenotypes, and outdated diagnostic classifications that do not reflect underlying pathophysiological mechanisms. Complicated studies and slow drug approvals will also hamper the Market's expansion.

To its rapid clinical developments and research into kidney disease therapies, North America is expected to dominate and lead the global Market for uncommon kidney disorders throughout the projected decade.
The key market players are GlaxoSmithKline, Recordati Rare Diseases, Amicus Therapeutics, Calliditas Therapeutics, Alexion Pharmaceuticals (A subsidiary of AstraZeneca), Travere Therapeutics, Aurinia Pharmaceutical, Advicenne, Protalix Biotherapeutics, AstraZeneca, Chinook Therapeutics, Reata Pharmaceuticals, Roche, Novartis Pharmaceuticals, Merk & co., Apellis Pharmaceuticals, Omeros Corporation, Lonza, and Other Prominent Players.

Key Developments in The Market:
• In Aug 2022, CSL Vifor and Travere Therapeutics announced that the European Medicines Agency (EMA) has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of a rare kidney disorder IgAN, and a leading cause of end-stage kidney disease (ESKD).
• In Dec 2021, The FDA approved the first drug to reduce urine protein levels in IgA nephropathy, a rare kidney disease. Tarpeyo (budesonide) delayed-release capsules have been granted accelerated approval by the FDA to minimise proteinuria (increased protein levels in the urine) in adults with primary immunoglobulin A (IgA) nephropathy who are at risk of rapid disease progression.
• In Sept 2021, Allarity Therapeutics and Lonza agreed to collaborate on developing and manufacturing dovitinib, Allarity's renal cell carcinoma candidate therapy. The agreement called for the start of dovitinib manufacturing in 2022 to meet Allarity's projected needs for bringing dovitinib to market after regulatory approvals.
• In June 2021, Novartis announced new Phase II interim data for iptacopan in the rare kidney disease C3 glomerulopathy (C3G). Iptacopan is being developed for a number of (CDRDs) complement-driven renal diseases, including C3Gand (IgAN) IgA nephropathy, the blood disorder paroxysmal nocturnal hemoglobinuria (PNH), with the goal of addressing a vital driver of these diseases.

Unlock Your GTM Strategy:https://www.insightaceanalytic.com/customisation/1414

Market Segmentation

Rare Kidney Diseases Market, by Target Indication, 2022-2030 (Value US$ Mn)
• IgA Nephropathy
• Lupus Nephritis
• Focal Segmental Glomerular Sclerosis
• Membranous Nephropathy
• C3 Glomerulopathy
• Cystinosis
• Dense Deposit Disease
• Distal Renal Tubular Acidosis
• Fabry Disease
• Refractory Gout
• Atypical Hemolytic Uremic Syndrome
• Others

Rare Kidney Diseases Market, by Type of Molecule, 2022-2030 (Value US$ Mn)
• Small Molecules
• Biologics
o Monoclonal Antibody
o Hormone
o Recombinant Protein
o Others

Rare Kidney Diseases Market, by Route of Administration, 2022-2030 (Value US$ Mn)
• Oral
• Intravenous
• Subcutaneous
• Others

Rare Kidney Diseases Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada

Europe Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Rare Kidney Diseases Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/1414

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.